Immunotherapy plus chemoradiation for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding an immunotherapy drug called sintilimab to standard chemoradiotherapy (chemo and radiation) is better than chemoradiotherapy alone for a specific type of nasopharyngeal cancer that has spread to neck lymph nodes. Immunotherapy uses your own immune system to fight cancer, and the hope is that adding it before and after standard treatment can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a recent diagnosis of nasopharyngeal carcinoma confirmed by biopsy.
- You must be 18 years or older.
- Your cancer must be at a certain stage, specifically spread to lymph nodes in the neck, but not to other parts of the body.
- You must be in good overall health, able to carry out daily activities, and have adequate blood cell counts and liver/kidney function.
- You cannot have certain medical conditions like active hepatitis B or C, HIV, interstitial lung disease, or an active autoimmune disease.
- You cannot be pregnant, breastfeeding, or allergic to the study drug, and you must not have had other cancers recently (except certain minor ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests whether adding an extra treatment after standard chemoradiation can reduce the chance of nasopharyngeal cancer coming back. The new treatment combines an immunotherapy drug (sintilimab) with a chemotherapy pill (capecitabine) for a year.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.